Transition times in the pharma universe
Express Pharma
MARCH 7, 2024
In fact, BMS has just announced a $100 million investment in Hyderabad for a new facility which will expand the company’s global drug development, IT and digital capabilities.
Drug Development Packaging Vaccines 
103 
STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts
STAT
OCTOBER 10, 2023
The state’s biotech scene exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. And although many companies are making layoffs, others are expanding. Absolutely.”
Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Life sciences sector to receive £650 million funding
European Pharmaceutical Review
MAY 26, 2023
The UK Chancellor has announced a £650 million life sciences growth package (Life Sci for Growth) to help deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills.
Mitigating fill, finish and CCI challenges for injectables
Express Pharma
MAY 10, 2023
However, this philosophy isn’t just relegated to guiding the practices of medical professionals and drug developers. It extends all the way down to the healthcare sector’s expectations for every component, instrument, and process orbiting the development and manufacture of medicine—especially parenteral drugs.
Industry backlash may reshape EU compulsory pharma licensing reform: GlobalData
Express Pharma
AUGUST 20, 2023
Both Johnson & Johnson and Pfizer criticised the changes by referencing the positive role of patents in incentivising their vaccine production during the COVID-19 pandemic. Even generics giant Teva Pharmaceuticals – a potential beneficiary of the reform – echoed the innovative drug developers’ preference for a voluntary licensing scheme.
Transdermal and Microneedle Drug Delivery 2023
pharmaphorum
OCTOBER 12, 2022
Engage in the latest innovations in device design, development and formulation, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease. Microneedle Device Developers. Microarray Patch Developers.
Automation to guide technology shift in aseptic environments
European Pharmaceutical Review
MAY 29, 2023
Despite this, only 13 nanomedicines had been approved by the US Food and Drug Administration (FDA) before 2015. Another 563 new nanomedicines were under clinical trial or in other stages of drug development. Nanoparticle HIV vaccine shows potential in trial Nanomedicines generally require aseptic processing.
Let's personalize your content